Monoclonal antibodies (mAbs) against EGFR have been developed for cancer treatment; e.g., cetuximab (a mouse–human chimeric mAb; IgG1) against head and neck and colorectal cancers; panitumumab (a fully human mAb; IgG2) against colorectal cancers; and necitumumab (a fully human mAb; IgG1) against non-small cell lung cancers [8], [9], [10]. Here, EGFR is linked to cancer.